MacroGenics (MGNX) Revenue & Revenue Breakdown
MacroGenics Revenue Highlights
Latest Revenue (Y)
$58.75M
Latest Revenue (Q)
$10.80M
Main Segment (Y)
Revenue From Collaborative Agreements
MacroGenics Revenue by Period
MacroGenics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $58.75M | -61.33% |
| 2022-12-31 | $151.94M | 100.87% |
| 2021-12-31 | $75.64M | -22.63% |
| 2020-12-31 | $97.76M | 57.62% |
| 2019-12-31 | $62.02M | 3.17% |
| 2018-12-31 | $60.12M | -61.34% |
| 2017-12-31 | $155.52M | 79.62% |
| 2016-12-31 | $86.58M | -14.15% |
| 2015-12-31 | $100.85M | 113.38% |
| 2014-12-31 | $47.26M | -16.72% |
| 2013-12-31 | $56.75M | -4.85% |
| 2012-12-31 | $59.65M | 26.76% |
| 2011-12-31 | $47.05M | - |
MacroGenics generated $58.75M in revenue during NA 2023, up -61.33% compared to the previous quarter, and up 97.72% compared to the same period a year ago.
MacroGenics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $10.80M | 18.60% |
| 2024-03-31 | $9.10M | -15.07% |
| 2023-12-31 | $10.72M | 3.11% |
| 2023-09-30 | $10.40M | -20.85% |
| 2023-06-30 | $13.14M | -45.75% |
| 2023-03-31 | $24.21M | -65.98% |
| 2022-12-31 | $71.18M | 70.55% |
| 2022-09-30 | $41.73M | 60.47% |
| 2022-06-30 | $26.01M | 143.67% |
| 2022-03-31 | $10.67M | -21.66% |
| 2021-12-31 | $13.62M | -12.54% |
| 2021-09-30 | $15.58M | -48.71% |
| 2021-06-30 | $30.37M | 88.98% |
| 2021-03-31 | $16.07M | -68.94% |
| 2020-12-31 | $51.75M | 197.13% |
| 2020-09-30 | $17.41M | 11.38% |
| 2020-06-30 | $15.64M | 20.58% |
| 2020-03-31 | $12.97M | -47.19% |
| 2019-12-31 | $24.56M | 36.54% |
| 2019-09-30 | $17.98M | 80.07% |
| 2019-06-30 | $9.99M | 5.16% |
| 2019-03-31 | $9.50M | -42.27% |
| 2018-12-31 | $16.45M | -20.21% |
| 2018-09-30 | $20.62M | 11.13% |
| 2018-06-30 | $18.55M | 312.18% |
| 2018-03-31 | $4.50M | -97.08% |
| 2017-12-31 | $154.31M | 14240.80% |
| 2017-09-30 | $1.08M | -0.46% |
| 2017-06-30 | $1.08M | -15.41% |
| 2017-03-31 | $1.28M | -86.51% |
| 2016-12-31 | $9.48M | 370.51% |
| 2016-09-30 | $2.01M | -97.43% |
| 2016-06-30 | $78.50M | 4046.70% |
| 2016-03-31 | $1.89M | -76.85% |
| 2015-12-31 | $8.18M | -44.30% |
| 2015-09-30 | $14.68M | 118.60% |
| 2015-06-30 | $6.72M | -90.58% |
| 2015-03-31 | $71.28M | 1201.66% |
| 2014-12-31 | $5.48M | -70.21% |
| 2014-09-30 | $18.38M | 99.37% |
| 2014-06-30 | $9.22M | -37.36% |
| 2014-03-31 | $14.72M | -1.26% |
| 2013-12-31 | $14.91M | -26.32% |
| 2013-09-30 | $20.23M | 64.52% |
| 2013-06-30 | $12.30M | 16.04% |
| 2013-03-31 | $10.60M | 8.16% |
| 2012-12-31 | $9.80M | -39.07% |
| 2012-09-30 | $16.08M | - |
MacroGenics generated $10.80M in revenue during Q2 2024, up 18.60% compared to the previous quarter, and up 44.59% compared to the same period a year ago.
MacroGenics Revenue Breakdown
MacroGenics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Revenue From Government Agreements | $1.56M | $1.92M | $1.80M | $7.12M | $2.16M |
| Revenue From Collaborative Agreements | $28.99M | $119.30M | $63.29M | $97.76M | $62.02M |
| Product | $17.94M | $16.73M | $12.35M | - | - |
| Contract Manufacturing | $9.83M | $13.99M | - | - | - |
MacroGenics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Revenue From Collaborative Agreements (49.71%), Product (30.76%), Contract Manufacturing (16.86%), and Revenue From Government Agreements (2.67%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RevenueFromCollaborativeAgreementsMember | $1.45M | $885.00K | $6.02M | $16.69M | $35.67M | $16.86M | $7.09M | $11.99M | $27.17M | $15.18M | $17.41M | $15.64M | $12.97M | $17.98M | - | - | - | - | - | - |
| RevenueFromGovernmentAgreementsMember | $358.00K | $345.00K | $466.00K | $283.00K | $547.00K | $480.00K | $428.00K | $85.00K | $386.00K | $810.00K | $838.00K | $4.62M | $715.00K | $757.00K | - | - | - | - | - | - |
| Product | $4.86M | $4.69M | $4.70M | $5.06M | $3.49M | $4.10M | $4.37M | $4.67M | $3.58M | $4.67M | $3.59M | $3.20M | $887.00K | - | - | - | - | - | - | - |
| Contract Manufacturing | $2.28M | $169.00K | $4.46M | $1.59M | $3.62M | $8.85M | $1.14M | $3.99M | - | - | - | - | - | - | - | - | - | - | - | - |
| Revenue From Collaborative Agreements | - | - | - | - | - | $59.67M | $8.96M | $51.75M | $24.56M | - | - | - | - | - | - | - | - | - | - | - |
| Revenue From Government Agreements | - | - | - | - | - | $468.00K | $523.00K | $945.00K | $636.00K | - | - | - | - | - | - | - | - | - | - | - |
| RevenuesFromLicenseAgreementsMember | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.00M |
| RevenuesFromGrantsMember | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $400.00K |
MacroGenics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (54.35%), Contract Manufacturing (25.45%), RevenueFromCollaborativeAgreementsMember (16.20%), and RevenueFromGovernmentAgreementsMember (4.00%).
MacroGenics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| MGNX | MacroGenics | $58.75M | $10.80M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| KZR | Kezar Life Sciences | $7.00M | - |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| CGEM | Cullinan Oncology | - | - |
| CCCC | C4 Therapeutics | - | - |
| ANTX | AN2 Therapeutics | - | - |
| PHVS | Pharvaris | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| NGM | NGM Biopharmaceuticals | - | $165.00K |
| NKTX | Nkarta | - | - |
| INZY | Inozyme Pharma | - | - |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| PMVP | PMV Pharmaceuticals | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| ZNTL | Zentalis Pharmaceuticals | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| PEPG | PepGen | - | - |
| TYRA | Tyra Biosciences | - | - |
MGNX Revenue FAQ
What is MacroGenics’s yearly revenue?
MacroGenics's yearly revenue for 2023 was $58.75M, representing a decrease of -61.33% compared to 2022. The company's yearly revenue for 2022 was $151.94M, representing an increase of 100.87% compared to 2021. MGNX's yearly revenue for 2021 was $75.64M, representing a decrease of -22.63% compared to 2020.
What is MacroGenics’s quarterly revenue?
MacroGenics's quarterly revenue for Q2 2024 was $10.8M, a 18.60% increase from the previous quarter (Q1 2024), and a -17.81% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $9.1M, a -15.07% decrease from the previous quarter (Q4 2023), and a -62.40% decrease year-over-year (Q1 2023). MGNX's quarterly revenue for Q4 2023 was $10.72M, a 3.11% increase from the previous quarter (Q3 2023), and a -84.94% decrease year-over-year (Q4 2022).
What is MacroGenics’s revenue growth rate?
MacroGenics's revenue growth rate for the last 3 years (2021-2023) was -22.33%, and for the last 5 years (2019-2023) was -5.28%.
What are MacroGenics’s revenue streams?
MacroGenics's revenue streams in c 23 are Revenue From Government Agreements, Revenue From Collaborative Agreements, Product, and Contract Manufacturing. Revenue From Government Agreements generated $1.56M in revenue, accounting 2.67% of the company's total revenue, down -19.08% year-over-year. Revenue From Collaborative Agreements generated $28.99M in revenue, accounting 49.71% of the company's total revenue, down -75.70% year-over-year. Product generated $17.94M in revenue, accounting 30.76% of the company's total revenue, up 7.25% year-over-year. Contract Manufacturing generated $9.83M in revenue, accounting 16.86% of the company's total revenue, down -29.70% year-over-year.
What is MacroGenics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of MacroGenics was Revenue From Collaborative Agreements. This segment made a revenue of $28.99M, representing 49.71% of the company's total revenue.